Category: Pharma, Life Sciences & Med Tech Players
-
Federal Circuit partly grants Bayer second chance in defending rivaroxaban patent invalidation campaign
The Federal Circuit has partly affirmed and partly vacated a United States Patent and Trademark Office’s Patent Trial and Appeal Board decision that deemed one of Bayer’s rivaroxaban-related patents invalid, in a three-year case initiated by rivals Mylan Pharmaceuticals, Teva Pharmaceuticals, and Invagen Pharmaceuticals.
-
Moderna, Alnylam settle U.S. COVID vaccine patent infringement dispute
Alnylam has settled its three-year dispute against Moderna in the District of Delaware, after a precedential Federal Circuit decision found the patentee had acted as its own lexicographer in defining a key patent specification term, foreclosing its infringement allegations.
-
Doctrine of equivalents removes painkiller from German market: Grünenthal wins preliminary injunction on appeal
A pharma patent and unfair competition dispute has taken a remarkable turn as the Dusseldorf Higher Regional Court granted a preliminary injunction based on infringement by equivalents.
-
Regeneron makes strides in global Eylea patent enforcement campaign: settles with Sandoz, files fresh UK suits
Regeneron has settled its year-long patent infringement dispute with Sandoz over several patents related to its eye disease drug Eylea, and filed a fresh lawsuit against two more rivals over the same drug in the High Court of Justice for England & Wales.
-
Pharma and Biotech Patent Litigation Summit Europe returns in 2026: rebranded event features tech industry track, UPC litigation forum
Kisaco Research’s annual Pharma and Biotech Patent Litigation Summit Europe will take place from January 19 to January 21 in the Beurs van Berlage, Amsterdam, with ip fray as an official media partner.
-
Pfizer, BioNTech hit back against GSK mRNA suits in UPC, Ireland: file UK revocation action
The move does not come as a major surprise, given the pharma companies’ previous success against GlaxoSmithKline in the UK.
-
Stanford retains cancer detection patents licensed to Foresight Diagnostics, but Roche gets non-exclusive license: settlement
Roche Molecular Systems, Stanford and Foresight Diagnostics have recently settled a dispute over trade secrets, breach of contract, unfair competition and patent ownership.
-
Post-judgment cleanup orders in UK pharma cases: no disgorgement of Bayer profits; Teva, Glenmark, Generics (UK) recover two thirds of costs
AstraZeneca must reimburse two thirds of the costs of an unsuccessful case Teva, Glenmark and Generics (UK). Separately, Bayer does not have to disgorge profits to Sandoz.
-
Boehringer wins nintedanib PI against Zentiva as UPC CoA reverses Lisbon LD on when infringement is imminent, clarifies how to argue national law
Context: Three months ago, the Unified Patent Court’s (UPC) Lisbon Local Division (LD) denied an application for provisional measures (which in some other jurisdictions would be called a motion for a preliminary injunction (PI)) by Boehringer Ingelheim against Zentiva, holding that an infringement did not appear imminent (item 2 of our May 10, 2025 UPC…